Down-regulation of TROP2 was previously shown to inhibit chemotherapy-induced keratinocyte apoptosis [29] and a TROP2-targeting approach demonstrated robust antitumor activity in triple-negative breast cancer [30]. The gene discussed is TACSTD2; the disease is triple-negative breast carcinoma.